Diligence memo · auto-generated · as of July 2, 2026
SRT Therapeutics, Inc.
SRT Therapeutics, Inc. looks over-valued against its niche peers and is active on financing cadence.
Businessfiled
SRT Therapeutics, Inc. operates in Biotechnology, based in San Diego.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
SRT Therapeutics, Inc. has raised $47M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $47M on 2025-04-04.
Most recent recorded round closed around 2025-04-04.
Valuation (modeled)modeled
Provath models SRT Therapeutics, Inc. at approximately $317M (range $147M–$434M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.65× the median modeled value of Series C Biotechnology companies in 2025–2027 (58 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 15 mo ago; this sector typically re-raises about every 14 months.
Raising on or ahead of the sector's normal rhythm.
Comparablesmixed
Capital scale ranks ahead of 81% of Biotechnology peers (4293 compared).
Modeled value ranks above 77% of those peers.
Closest niche peers: Newleos Therapeutics, Inc., Biolinq Inc, Atsena Therapeutics, Inc., Galvanize Therapeutics, Inc., X4 Pharmaceuticals, Inc.
Peoplefiled
6 named people on file across officers, directors and signatories.
Risks & flagsmixed
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.